INSIGHTS ON ENTERPRISE SOLUTIONS
-
![Primrose Bio - CORRECTION Bioprocess Online_Primrose Scientific Poster_Overcoming ncAA Production Bottlenecks Melanie]( "High-Titer Antibody Expression With 100% pAzF Incorporation At Scale And Minimal Host Toxicity")
High-Titer Antibody Expression With 100% pAzF Incorporation At Scale And Minimal Host ToxicityLearn how rational design and optimized feed strategies enable high-titer protein expression and full incorporation of non-canonical amino acids at scale, overcoming common toxicity and yield bottlenecks.
-
![GettyImages-657049264 manufacturing]( "Increase Agility By Integrating Drug Substance And Drug Product")
Increase Agility By Integrating Drug Substance And Drug ProductBiopharma success depends on agility. Move efficiently from discovery to delivery by co-locating drug substance and drug product operations, reducing transfer risks and accelerating your timeline
-
![GettyImages-1135385738-scientist-gloves-pen-and-clipboard]( "CDMO Checklist To Choose The Right Aseptic Isolator")
CDMO Checklist To Choose The Right Aseptic IsolatorSelecting the right isolator for aseptic filling requires more than comparing features. Discover essential questions to ask and make informed decisions that align with your process and operational goals.
-
![The Editors’ Roundtable: A 2025 Retrospective Of The Life Science Industry]( "The Editors' Roundtable: A 2025 Retrospective Of The Life Science Industry")
The Editors' Roundtable: A 2025 Retrospective Of The Life Science IndustryIn this special edition of “Better Biopharma,” host Tyler Menichiello is joined by fellow chief editors from across the Life Science Connect ecosystem to reflect on the year and share their industry outlooks for 2026.
-
From The Floor At CPHI 2025: Takeaways Everyone Should Know12/23/2025
Gain insights into evolving pharma priorities, from supply chain resilience to advanced manufacturing, and why flexibility, scalability, and technical expertise matter in a dynamic global market.
-
CDMO Capabilities Overview12/23/2025
Explore global CDMO capabilities that streamline drug development and manufacturing, leveraging advanced infrastructure and regulatory expertise from early formulation through commercial production.
-
Corporate Overview 2025: Business Strategy & Outlook12/23/2025
Explore how a growing pharma organization uses innovation, regulatory expertise, and strategic partnerships to deliver targeted therapies and drive impact across the evolving healthcare landscape.
-
State-Of-The-Art CDMO Facility - Maple Grove12/22/2025
Discover how a U.S.-based CDMO combines advanced infrastructure, quality-driven processes, and flexible manufacturing to support pharmaceutical development and commercial supply.
ENTERPRISE SOLUTIONS
-
![Cytiva inspection support]( "Aseptic Filling Inspection Support Service")
Prepare for GMP audits with confidence through expert guidance and tailored coaching. Explore how this service helps you navigate the regulatory complexities of advanced aseptic filling systems.
-
![GettyImages-506999858-scientists-cell-culture-lab-development]( "Viral Clearance Testing For Biologics, Vaccines & AAV Therapies")
Viral clearance protects patients by validating virus removal and inactivation in biologics manufacturing, meeting global standards through rigorous, audit-ready studies and expert oversight.
-
![Asahi Kasei - VANTIJ]( "VANTIJ® Single-Use Virus Filtration Controller")
Automating critical filtration steps significantly reduces cross-contamination risks and operational costs. This single-use approach ensures process repeatability and eliminates cleaning downtime.
-
![GettyImages-1351826681-capping-vials-fill-finish]( "Aseptic Manufacturing: Fill/Finish For Vials, Syringes, Cartridges")
Sterile fill/finish requires isolator technology and regulatory compliance. From clinical development to commercial scale, technical expertise ensures the integrity of liquid and lyophilized injectables.
-
![GettyImages-2154728338 global]( "Minaris Advanced Therapies Overview")
Global cell and gene therapy CDMO providing GMP manufacturing, testing, and development services with commercial success, regulatory expertise, and advanced multi‑modality capabilities.
